CSL Limited (ASX:CSL) Insider Paul McKenzie Sells 4,000 Shares

CSL Limited (ASX:CSL) insider Paul McKenzie sold 4,000 shares of the business’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of A$287.15 ($190.17), for a total transaction of A$1,148,600.00 ($760,662.25).

Paul McKenzie also recently made the following trade(s):

• On Tuesday, September 3rd, Paul McKenzie bought 8,275 shares of CSL stock. The shares were acquired at an average price of A$306.03 ($202.67) per share, for a total transaction of A$2,532,398.25 ($1,677,084.93).

CSL Price Performance

The company has a quick ratio of 1.68, a current ratio of 2.17 and a debt-to-equity ratio of 62.80.

CSL Increases Dividend

The business also recently disclosed a Final dividend, which was paid on Tuesday, October 1st. Investors of record on Tuesday, October 1st were issued a $2.203 dividend. This is a positive change from CSL’s previous Final dividend of $1.99. This represents a yield of 0.73%. The ex-dividend date of this dividend was Sunday, September 8th. CSL’s payout ratio is 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.